Trump’s threat to impose tariffs on Mexico undermines his stated intention to eliminate the “chaos” at America’s southern ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein. The ...

While some tequila makers have warned they might have to implement price hikes to offset tariffs, Colorado-based Suerte ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new shingles vaccine ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former GSK leaders to its board. The biotech’s series B was led by new ...

Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round. The fresh cash will help Curevo advance Phase 2 trials of amezosvatein ...

This is the power of Soul & Science, giving clients unstoppable ideas and a decisive edge in their markets.” Mekanism Canada ...

Concurrent with the round, Moncef Slaoui, PhD, will join Curevo as Board Chair. Dr. Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed during the COVID-19 pandemic ...